Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using 99mtechnetium-labeled anti-KL-6/MUC1 antibody

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 26, Issue 3, 2008, Pages 133-139

  Matsumura, Kenji ^a   Niki, Ichiro ^a   Tian, Hui ^a   Takuma, Masahisa ^a   Hongo, Norio ^a   Matsumoto, Shunro ^a   Mori, Hiromu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

KL 6; Monoclonal antibody; MUC1; Pancreatic cancer; Radioimmunoscintigraphy

Indexed keywords

KL 6 ANTIBODY; PROTEIN ANTIBODY; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CA-15-3 ANTIGEN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RADIOIMMUNODETECTION; TECHNETIUM; TUMOR CELLS, CULTURED;

EID: 43249089522     PISSN: 02882043     EISSN: 18625274     Source Type: Journal    
DOI: 10.1007/s11604-007-0207-6     Document Type: Article

References (32)

1. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006;73:485-492.
2. Tezel E, Kaneko T, Sugimoto H, Takeda S, Inoue S, Nagasaka T, et al. Clinical significance of intraportal endovascular ultrasonography for the diagnosis of extrapancreatic nerve plexus invasion by pancreatic carcinoma. Pancreatology 2004;4:76-81.
3. Smith JR, Oates E. Radionuclide imaging of the thyroid gland: patterns, pearls, and pitfalls. Clin Nucl Med 2004;29:181-193.
4. Clark AN, Beller GA. The present role of nuclear cardiology in clinical practice. Q J Nucl Med Mol Imaging 2005;49:43-58.
5. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004;22:3593-3607.
6. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001;72:839-845.
7. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003;17:143-152.
8. Karube Y, Katsuno K, Takata J, Matsunaga K, Haruno M, Kuroki M, et al. Radioimmunoscintigraphy using technetium-99m-labeled parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen in athymic nude mice bearing tumors. Nucl Med Biol 1996;23:753-759.
9. 99mtechnetium labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models. Q J Nucl Med 2003;47:139-144.
10. Bian HJ, Chen ZN, Deng JL. Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radio-immunoconjugate for hepatocellular carcinoma imaging. World J Gastroenterol 2000;6:348-352.
11. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res 1997;50:393-401.
12. Steinstrasser A, Oberhausen E. Anti-CEA labeling kit BW 431/26, results of the European multicenter trial. Nuklearmedizin 1995;34:232-242.
13. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006;24:252-258.
14. 99mTc conjugate for immunoscintigraphy of bladder cancer. Urol Res 2001;29:13-19.
15. Schuhmacher J, Kaul S, Klivenyi G, Jundermann H, Magener A, Henze M, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 2001;61:3712-3717.
16. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203-216.
17. Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl 1004;8:6-26.
18. Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994;8:81-83.
19. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
20. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999;46:151-158.
21. Hamada H, Kohno N, Hiwada K. A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma. Jpn J Cancer Res 1994;85:211-219.
22. Hamada H, Kohno N, Yokoyama A, Kondo K, Yang SZ, Hiwada K, et al. A novel monoclonal antibody, H9, directed against the core protein of MUC1 mucin. Oncol Rep 2000;7:225-232.
23. Balthazar EJ. Pancreatitis associated with pancreatic carcinoma: preoperative diagnosis: role of CT imaging in detection and evaluation. Pancreatology 2005;5:330-344.
24. Van Gulik TM, Moojen TM, van Geenen R, Rauws EA, Obertop H, Gouma DJ. Differential diagnosis of focal pancreatitis and pancreatic cancer. Ann Oncol 1999;10(suppl 4):85-88.
25. Farnell MB, Pearson RK, Sarr MG, Dimagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-630.
26. Pedrazzoli S, Pasquali C, Sperti C. General aspects of surgical treatment of pancreatic cancer. Dig Surg 1999;16:265-275.
27. Berberat P, Friess H, Kashiwagi M, Beger HG, Büchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999;23:882-887.
28. Zimny M. Diagnostic imaging of pancreatic cancer: the role of PET. Front Radiat Ther Oncol 2004;38:67-75.
29. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Dol R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET): usefulness and limitations in "clinical reality." Ann Nucl Med 2003;17:261-279.
30. 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000;24:1121-1129.
31. Nishiyama Y, Yamamoto Y, Yokoe K, Monden T, Sasakawa Y, Tsutsui K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005;19:491-497.
32. 99mTc. Nucl Med Commun 2001;22:1089-1094.